{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:37:01Z","timestamp":1772163421193,"version":"3.50.1"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2022,9,4]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The gut microbiome and its metabolites are influenced by age and stress and reflect the metabolism and health of the immune system. We assessed the gut microbiota and faecal metabolome in a static animal model of non-alcoholic steatohepatitis (NASH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This model was subjected to the following treatments: reverse osmosis water, AFO-202, N-163, AFO-202+N-163 and telmisartan treatment. Faecal samples were collected at 6 and 9 weeks of age. The gut microbiome was analysed using 16S ribosomal RNA sequences acquired by next-generation sequencing, and the faecal metabolome was analysed using gas chromatography-mass spectrometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Gut microbial diversity increased greatly in the AFO-202+N-163 group. Postintervention, the abundance of Firmicutes decreased, whereas that of Bacteroides increased and was the highest in the AFO-202+N-163 group. The decrease in the abundance of Enterobacteriaceae and other Firmicutes and the abundance of Turicibacter and Bilophila were the highest in the AFO-202 and N-163 groups, respectively. Lactobacillus abundance was highest in the AFO-202+N-163 group. The faecal metabolite spermidine, which is beneficial against inflammation and NASH, was significantly decreased (p=0.012) in the N-163 group. Succinic acid, which is beneficial in neurodevelopmental and neurodegenerative diseases, was increased in the AFO-202 group (p=0.06). The decrease in fructose was the highest in the N-163 group (p=0.0007). Isoleucine and Leucine decreased with statistical significance (p=0.004\u2009and 0.012, respectively), and tryptophan also decreased (p=0.99), whereas ornithine, which is beneficial against chronic immune-metabolic-inflammatory pathologies, increased in the AFO-202+N-163 group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AFO-202 treatment in mice is beneficial against neurodevelopmental and neurodegenerative diseases, and has prophylactic potential against metabolic conditions. N-163 treatment exerts anti-inflammatory effects against organ fibrosis and neuroinflammation. In combination, these compounds exhibit anticancer activity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2022-000985","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T12:20:20Z","timestamp":1664281220000},"page":"e000985","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":20,"title":["Two unique biological response-modifier glucans beneficially regulating gut microbiota and faecal metabolome in a non-alcoholic steatohepatitis animal model, with potential applications in human health and disease"],"prefix":"10.1136","volume":"9","author":[{"given":"Senthilkumar","family":"Preethy","sequence":"first","affiliation":[{"name":"Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobunao","family":"Ikewaki","sequence":"additional","affiliation":[{"name":"Dept. of Medical Life Science, Kyushu University of Health and Welfare, Nobeoka, Japan"},{"name":"Institute of Immunology, Junsei Educational Institute, Nobeoka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary A","family":"Levy","sequence":"additional","affiliation":[{"name":"Medicine and Immunology, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kadalraja","family":"Raghavan","sequence":"additional","affiliation":[{"name":"Dept of Paediatric Neurology, Jesuit Antonyraj memorial Inter-disciplinary Centre for Advanced Recovery and Education (JAICARE), Madurai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidyasagar Devaprasad","family":"Dedeepiya","sequence":"additional","affiliation":[{"name":"Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Genome Medical Sciences Project, National Center for Global Health and Medicine (NCGM), Kohnodai, Chiba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramaniam","family":"Srinivasan","sequence":"additional","affiliation":[{"name":"Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natarajan","family":"Ranganathan","sequence":"additional","affiliation":[{"name":"R & D, Kibow Biotech Inc, Pennsylvania, Newtown Square, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajappa","family":"Senthilkumar","sequence":"additional","affiliation":[{"name":"Fujio-Eiji Academic Terrain (FEAT), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-2687","authenticated-orcid":false,"given":"Samuel J K","family":"Abraham","sequence":"additional","affiliation":[{"name":"Mary-Yoshio Translational Hexagon (MYTH), Nichi-In Centre for Regenerative Medicine (NCRM), Chennai, India"},{"name":"Centre for Advancing Clinical Research (CACR), University of Yamanashi - School of Medicine, Chuo, Japan"},{"name":"Antony- Xavier Interdisciplinary Scholastics (AXIS), GN Corporation Co. Ltd, Kofu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"2025073012513027000_9.1.e000985.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2179"},{"key":"2025073012513027000_9.1.e000985.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2015.11.012"},{"key":"2025073012513027000_9.1.e000985.3","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000139"},{"key":"2025073012513027000_9.1.e000985.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0135-7"},{"key":"2025073012513027000_9.1.e000985.5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2012\/895370","article-title":"Potential effects of nichi glucan as a food supplement for diabetes mellitus and hyperlipidemia: preliminary findings from the study on three patients from India","volume":"2012","author":"Dedeepiya","year":"2012","journal-title":"Case Rep Med"},{"key":"2025073012513027000_9.1.e000985.6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/19390211.2013.859211","article-title":"Beneficial effects of black yeast derived 1-3, 1-6 Beta Glucan-Nichi Glucan in a dyslipidemic individual of Indian origin--a case report","volume":"11","author":"Ganesh","year":"2014","journal-title":"J Diet Suppl"},{"key":"2025073012513027000_9.1.e000985.7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2021-000203"},{"key":"2025073012513027000_9.1.e000985.8","unstructured":"Raghavan K , Dedeepiya VD , Kandaswamy R , et al . Improvement of sleep patterns and serum melatonin levels in children with autism spectrum disorders after consumption of beta-1,3\/1,6-glucan in a pilot clinical study. Brain and Behaviour."},{"key":"2025073012513027000_9.1.e000985.9","doi-asserted-by":"crossref","unstructured":"Raghavan K , Dedeepiya VD , Srinivasan S . Disease-Modifying immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 beta glucans in young boys with Duchenne muscular dystrophy: results of an open-label, prospective, randomized, comparative clinical study. medRxiv 2021.","DOI":"10.1101\/2021.12.13.21267706"},{"key":"2025073012513027000_9.1.e000985.10","doi-asserted-by":"crossref","unstructured":"Ikewaki N , Kurosawa G , Iwasaki M . Hepatoprotective effects of Aureobasidium pullulans derived beta 1,3-1,6 biological response modifier glucans in a STAM- animal model of non-alcoholic steatohepatitis. Journal of Clinical and Experimental Hepatology-2022 In Press 2021.","DOI":"10.1101\/2021.07.08.451700"},{"key":"2025073012513027000_9.1.e000985.11","doi-asserted-by":"crossref","unstructured":"Pushkala S , Seshayyan S , Theranirajan E . Efficient control of IL-6, CRP and ferritin in Covid-19 patients with two variants of Beta-1,3-1,6 glucans in combination, within 15 days in an open-label prospective clinical trial. medRxiv 2021;1267778.","DOI":"10.1101\/2021.12.14.21267778"},{"key":"2025073012513027000_9.1.e000985.12","doi-asserted-by":"crossref","first-page":"112243","DOI":"10.1016\/j.biopha.2021.112243","article-title":"Beneficial effects of novel Aureobasidium pullulans strains produced beta-1,3-1,6 glucans on interleukin-6 and D-dimer levels in COVID-19 patients; results of a randomized multiple-arm pilot clinical study","volume":"145","author":"Raghavan","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"2025073012513027000_9.1.e000985.13","doi-asserted-by":"crossref","unstructured":"Raghavan K , Dedeepiya VD , Yamamoto N , et al . Benefits of gut microbiota reconstitution by beta 1,3-1,6 glucans in subjects with autism spectrum disorder and other neurodegenerative diseases. Journal of Alzheimers Disease 2021.","DOI":"10.3233\/JAD-220388"},{"key":"2025073012513027000_9.1.e000985.14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091906","article-title":"Clinical and physiological perspectives of \u03b2-glucans: the past, present, and future","volume":"18","author":"Bashir","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2025073012513027000_9.1.e000985.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1348-0421.2007.tb03982.x"},{"key":"2025073012513027000_9.1.e000985.16","doi-asserted-by":"crossref","unstructured":"Ikewaki N , Onaka T , Ikeue Y . Beneficial effects of the AFO-202 and N-163 strains of Aureobasidium pullulans produced 1,3-1,6 beta glucans on non-esterified fatty acid levels in obese diabetic KKAy mice: a comparative study. bioRxiv 2021.","DOI":"10.1101\/2021.07.22.453362"},{"key":"2025073012513027000_9.1.e000985.17","doi-asserted-by":"crossref","unstructured":"Ikewaki N , Sonoda T , Kurosawa G . Immune and metabolic beneficial effects of beta 1,3-1,6 glucans produced by two novel strains of Aureobasidium pullulans in healthy middle-aged Japanese men: an exploratory study. medRxiv 2021.","DOI":"10.1101\/2021.08.05.21261640"},{"key":"2025073012513027000_9.1.e000985.18","unstructured":"Stam model. Available: https:\/\/www.smccro-lab.com\/service\/service_disease_area\/stam.html"},{"key":"2025073012513027000_9.1.e000985.19","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/fsn3.828","article-title":"Anti-fibrotic activity of Euglena gracilis and paramylon in a mouse model of non-alcoholic steatohepatitis","volume":"7","author":"Nakashima","year":"2019","journal-title":"Food Sci Nutr"},{"key":"2025073012513027000_9.1.e000985.20","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00039.2016"},{"key":"2025073012513027000_9.1.e000985.21","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809302"},{"key":"2025073012513027000_9.1.e000985.22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155214","article-title":"Gut microbiota metabolites in NAFLD pathogenesis and therapeutic implications","volume":"21","author":"Chen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025073012513027000_9.1.e000985.23","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1574-6968.1991.tb04564.x","article-title":"Isobutyrate as a precursor of n-butyrate in the biosynthesis of tylosine and fatty acids","volume":"68","author":"Rezanka","year":"1991","journal-title":"FEMS Microbiol Lett"},{"key":"2025073012513027000_9.1.e000985.24","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00314-20"},{"key":"2025073012513027000_9.1.e000985.25","doi-asserted-by":"publisher","DOI":"10.1128\/mSystems.00561-20"},{"key":"2025073012513027000_9.1.e000985.26","doi-asserted-by":"publisher","DOI":"10.1159\/000481401"},{"key":"2025073012513027000_9.1.e000985.27","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13026"},{"key":"2025073012513027000_9.1.e000985.28","doi-asserted-by":"crossref","first-page":"151513","DOI":"10.1016\/j.ijmm.2021.151513","article-title":"The role of fecal sulfur metabolome in inflammatory bowel diseases","volume":"311","author":"Walker","year":"2021","journal-title":"Int J Med Microbiol"},{"key":"2025073012513027000_9.1.e000985.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2017.12.008"},{"key":"2025073012513027000_9.1.e000985.30","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1711233114"},{"key":"2025073012513027000_9.1.e000985.31","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27105"},{"key":"2025073012513027000_9.1.e000985.32","doi-asserted-by":"publisher","DOI":"10.1097\/NT.0000000000000167"},{"key":"2025073012513027000_9.1.e000985.33","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.110.010132"},{"key":"2025073012513027000_9.1.e000985.34","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2020.1854008"},{"key":"2025073012513027000_9.1.e000985.35","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26022"},{"key":"2025073012513027000_9.1.e000985.36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.638148","article-title":"Probiotics in cancer","volume":"11","author":"Lu","year":"2021","journal-title":"Front Oncol"},{"key":"2025073012513027000_9.1.e000985.37","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13397","article-title":"The alteration of the gut microbiome by immunosuppressive agents used in solid organ transplantation","volume":"23","author":"Gibson","year":"2021","journal-title":"Transpl Infect Dis"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2022-000985","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T19:51:38Z","timestamp":1753905098000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2022-000985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,9,27]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/bmjgast-2022-000985"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2022-000985","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.06.23.497433","asserted-by":"object"}]},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}